Dr. Abrams is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana 1220
Boston, MA 02115Phone+1 617-632-6932Fax+1 617-632-5370
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2003 - 2006- University of MichiganResidency, Internal Medicine, 2000 - 2003
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000
Certifications & Licensure
MA State Medical License 2006 - 2025
FL State Medical License 2016 - 2018
NH State Medical License 2010 - 2018
MI State Medical License 2000 - 2008- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer Start of enrollment: 2009 Jun 01
- Sorafenib + mFOLFOX for Hepatocellular Carcinoma Start of enrollment: 2013 Jan 01
- HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) Start of enrollment: 2013 May 01
- Join now to see all
Publications & Presentations
PubMed
- 105 citationsIdentification of Potentially Avoidable Hospitalizations in Patients With GI CancerGabriel A. Brooks, Thomas A. Abrams, Jeffrey A. Meyerhardt, Peter C. Enzinger, Karen Sommer
Journal of Clinical Oncology. 2014-02-20 - 59 citationsCombined PD-1, BRAF and MEK inhibition in BRAFcolorectal cancer: a phase 2 trial.Jun Tian, Jonathan H Chen, Sherry X Chao, Karin Pelka, Marios Giannakis
Nature Medicine. 2023-02-01 - 48 citationsNCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.Al B Benson, Michael I D'Angelica, Thomas Abrams, Daniel E Abbott, Aijaz Ahmed
Journal of the National Comprehensive Cancer Network. 2023-07-01
Press Mentions
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022January 18th, 2022
New Paradigm Emerging in Advanced Pancreatic CancerMay 25th, 2016- Partnering With Patients: A Collection of Perspectives From ASCO 2023September 7th, 2023
Committees
- Member, National Comprehensive Cancer Network (NCCN) Hepatobiliary Cancers Guidelines Committee 2008 - Present
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
